肥胖治疗的新药和在研药物进展
Progress of New Drugs and Drugs in Research for Obesity Treatment
DOI: 10.12677/ACM.2021.1111758, PDF,    国家自然科学基金支持
作者: 张小春, 张丽君, 赵妍妍, 梁向艳, 赵玉峰*：西安医学院基础医学研究所，陕西 西安
关键词: 肥胖；药物；在研药物；作用靶点；Obesity； Drugs； Drugs in Research； Drug Targets
摘要: 肥胖改变机体代谢状态，显著增加糖尿病、心血管病等多种疾病风险，已经对我国造成严重经济和社会负担，肥胖治疗药物一直是研发热点。2019年以来，FDA批准了PLENITY和Imcivree两种新药用于肥胖治疗。本文对PLENITY和Imcivree这两种药物进行详细介绍，并对目前处于不同研发阶段的其它在研药物进行总结，以期加深对肥胖治疗现状和前景的认识。
Abstract: Obesity induces the change in body metabolic state and significantly increases the risk of various diseases such as diabetes and cardiovascular diseases. It has already led to severe economic and social burden on our country. Development of obesity treatment drugs is a hot topic at present. Since 2019, FDA has approved two new drugs, PLENITY and Imcivree, for obesity treatment. This article introduces PLENITY and Imcivree in detail, and summarizes other candidate drugs at different research and development stages, which aims to deepen the understanding of the current situation and prospect of obesity treatment.
文章引用：张小春, 张丽君, 赵妍妍, 梁向艳, 赵玉峰. 肥胖治疗的新药和在研药物进展[J]. 临床医学进展, 2021, 11(11): 5138-5143. https://doi.org/10.12677/ACM.2021.1111758

参考文献

[1] Purnell, J.Q. (2000) Definitions, Classification, and Epidemiology of Obesity. MDText.com, Inc., South Dartmouth.
[2] Wang, L., Zhou, B., Zhao, Z., Yang, L., Zhang, M., Jiang, Y., et al. (2021) Body-Mass Index and Obesity in Urban and Rural China: Findings from Consecutive Nationally Representative Surveys during 2004-18. Lancet, 398, 53-63. [Google Scholar] [CrossRef] 
[3] 张娟, 施小明, 梁晓峰. 2010年中国城乡居民超重和肥胖的直接经济负担分析[J]. 中华流行病学杂志, 2013, 34(6): 598-600.
[4] The GBD 2015 Obesity Collaborators (2017) Health Effects of Overweight and Obesity in 195 Countries over 25 Years. The New England Journal of Medicine, 377, 13-27. [Google Scholar] [CrossRef] 
[5] 覃潆玉, 刘佳瑞, 郑瑞茂. 肥胖治疗的研究进展[J]. 生理科学进展, 2020, 51(3): 167-173.
[6] 张书文, 杨德英. 肥胖症药物治疗的研究及评价[J]. 中国保健营养旬刊(下旬刊), 2012, 22(1): 297-298.
[7] Greenway, F.L., Aronne, L.J., Raben, A., Astrup, A., Apovian, C.M., Hill, J.O., et al. (2019) A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity, 27, 205-216. [Google Scholar] [CrossRef] [PubMed]
[8] Clément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W.K., Connors, H., et al. (2020) Efficacy and Safety of Setmelanotide, an MC4R Agonist, in Individuals with Severe Obesity Due to LEPR or POMC Deficiency: Single-Arm, Open-Label, Multicentre, Phase 3 Trials. The lancet Diabetes & Endocrinology, 8, 960-970. [Google Scholar] [CrossRef] 
[9] Narayanaswami, V. and Dwoskin, L.P. (2017) Obesity: Current and Potential Pharmacotherapeutics and Targets. Pharmacology & Therapeutics, 170, 116-147. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, L., Sui, L., Panigrahi, S.K., Meece, K., Xin, Y., Kim, J., et al. (2017) PC1/3 Deficiency Impacts Pro-Opiomelanocortin Processing in Human Embryonic Stem Cell-Derived Hypothalamic Neurons. Stem Cell Reports, 8, 264-277. [Google Scholar] [CrossRef] [PubMed]
[11] Hainer, V., Aldhoon Hainerová, I., Kunešová, M., Taxová Braunerová, R., Zamrazilová, H. and Bendlová, B. (2020) Melanocortin Pathways: Suppressed and Stimulated Melanocortin-4 Receptor (MC4R). Physiological Research, 69, S245-S254. [Google Scholar] [CrossRef] [PubMed]
[12] Sharma, S., Garfield, A.S., Shah, B., Kleyn, P., Ichetovkin, I., Moeller, I.H., et al. (2019) Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation. Molecules, 24, Article No. 1892. [Google Scholar] [CrossRef] [PubMed]
[13] Appel, L., Bergström, M., Buus Lassen, J. and Långström, B. (2014) Tesofensine, a Novel Triple Monoamine Re-Uptake Inhibitor with Anti-Obesity Effects: Dopamine Transporter Occupancy as Measured by PET. European Neuropsychopharmacology, 24, 251-261. [Google Scholar] [CrossRef] [PubMed]
[14] Recinella, L., Chiavaroli, A., Ferrante, C., Mollica, A., Macedonio, G., Stefanucci, A., et al. (2018) Effects of Central RVD-Hemopressin(α) Administration on Anxiety, Feeding Behavior and Hypothalamic Neuromodulators in the Rat. Pharmacological Reports, 70, 650-657. [Google Scholar] [CrossRef] [PubMed]
[15] Astrup, A., Madsbad, S., Breum, L., Jensen, T.J., Kroustrup, J.P. and Meinert Larsen, T. (2008) Effect of Tesofensine on Bodyweight Loss, Body Composition, and Quality of Life in Obese Patients: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet, 372, 1906-1913. [Google Scholar] [CrossRef] 
[16] Shende, P. and Desai, D. (2020) Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions. In: Turksen, K., Ed., Cell Biology and Translational Medicine, Vol. 7, Vol. 1237, Springer, Cham, 37-47. [Google Scholar] [CrossRef] [PubMed]
[17] Farhadipour, M. and Depoortere, I. (2021) The Function of Gastrointestinal Hormones in Obesity-Implications for the Regulation of Energy Intake. Nutrients, 13, Article No. 1839. [Google Scholar] [CrossRef] [PubMed]
[18] Chia, C.W. and Egan, J.M. (2020) Incretins in Obesity and Diabetes. Annals of the New York Academy of Sciences, 1461, 104-126. [Google Scholar] [CrossRef] [PubMed]
[19] Bailey, C.J. (2021) Tirzepatide: A New Low for Bodyweight and Blood Glucose. The Lancet Diabetes & Endocrinology, 9, 646-648. [Google Scholar] [CrossRef] 
[20] Grudén, S., Forslund, A., Alderborn, G., Söderhäll, A., Hellström, P.M. and Holmbäck, U. (2021) Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose. Clinical Pharmacology in Drug Development, 10, 1242-1247. [Google Scholar] [CrossRef] [PubMed]
[21] Sugama, J., Moritoh, Y., Yashiro, H., Tsuchimori, K. and Watanabe, M. (2021) Enteropeptidase Inhibition Improves Obesity by Modulating Gut Microbiota Composition and Enterobacterial Metabolites in Diet-Induced Obese Mice. Pharmacological Research, 163, Articlr ID: 105337. [Google Scholar] [CrossRef] [PubMed]
[22] Rebello, C.J., Zemel, M.B., Kolterman, O., Fleming, G.A. and Greenway, F.L. (2021) Leucine and Sildenafil Combination Therapy Reduces Body Weight and Metformin Enhances the Effect at Low Dose: A Randomized Controlled Trial. American Journal of Therapeutics, 28, e1-e13. [Google Scholar] [CrossRef] 
[23] Shin, Y., Lee, D., Ahn, J., Lee, M., Shin, S.S. and Yoon, M. (2021) The Herbal Extract ALS-L1023 from Melissa officinalis Reduces Weight Gain, Elevated Glucose Levels and β-Cell Loss in Otsuka Long-Evans Tokushima Fatty Rats. Journal of Ethnopharmacology, 264, Article ID: 113360. [Google Scholar] [CrossRef] [PubMed]
[24] Woo, S., Yoon, M., Kim, J., Hong, Y., Kim, M.Y., Shin, S.S., et al. (2016) The Anti-Angiogenic Herbal Extract from Melissa officinalis Inhibits Adipogenesis in 3T3-L1 Adipocytes and Suppresses Adipocyte Hypertrophy in High Fat Diet-Induced Obese C57BL/6J Mice. Journal of Ethnopharmacology, 178, 238-250. [Google Scholar] [CrossRef] [PubMed]

为你推荐